Genenta Science S.p.A.

Genenta Science S.p.A. is an Italian clinical-stage biotechnology company that has recently embarked on a strategic transformation to evolve into an industrial consolidator. Historically focused on developing hematopoietic stem cell gene therapies for solid tumors, the company is now actively acquiring privately held Italian businesses in national security-regulated sectors, including defense, aerospace, and biotechnology. Headquartered in Milan, Italy, Genenta Science aims to forge Europe's next-generation industrial champions by integrating these specialized companies.

In its biotechnology segment, Genenta Science's lead product candidate is Temferon™, a first-in-class therapy designed to deliver immune-therapeutic payloads directly into the tumor microenvironment using genetically engineered hematopoietic stem cells. This platform targets solid tumor cancers, with ongoing Phase 1/2a clinical trials for glioblastoma multiforme and renal cell carcinoma. Concurrently, as an industrial consolidator, Genenta is expanding into new market segments through acquisitions, such as tactical rifles and special-forces weapon systems manufacturer ATC, and Sòphia High Tech, which produces critical mechanical components for space and defense systems.

Recent notable developments include the company's strategic pivot towards becoming an industrial consolidator, though a planned name change to Saentra Forge S.p.A. and ticker change to SAEN was recently cancelled, with the company continuing under its current name and ticker. Genenta has signed definitive agreements with Sòphia High Tech as part of this new strategy. Pierluigi Paracchi serves as the Co-Founder, Chairman, and CEO. The company also announced the closure of its U.S. subsidiary and the transition of its CFO to a consulting role. Genenta Science is publicly traded on NASDAQ under the symbol GNTA, with a market capitalization of approximately $16-17 million USD, and has received a Nasdaq notice regarding its sub-$1 bid price.